Last reviewed · How we verify

Isoniazid with HUEXC030 and RZE

Orient Pharma Co., Ltd. · Phase 2 active Small molecule

Isoniazid with HUEXC030 and RZE is a Small molecule drug developed by Orient Pharma Co., Ltd.. It is currently in Phase 2 development. Also known as: INH with HUEXC030, RMP, PZA and EMB.

At a glance

Generic nameIsoniazid with HUEXC030 and RZE
Also known asINH with HUEXC030, RMP, PZA and EMB
SponsorOrient Pharma Co., Ltd.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Isoniazid with HUEXC030 and RZE

What is Isoniazid with HUEXC030 and RZE?

Isoniazid with HUEXC030 and RZE is a Small molecule drug developed by Orient Pharma Co., Ltd..

Who makes Isoniazid with HUEXC030 and RZE?

Isoniazid with HUEXC030 and RZE is developed by Orient Pharma Co., Ltd. (see full Orient Pharma Co., Ltd. pipeline at /company/orient-pharma-co-ltd).

Is Isoniazid with HUEXC030 and RZE also known as anything else?

Isoniazid with HUEXC030 and RZE is also known as INH with HUEXC030, RMP, PZA and EMB.

What development phase is Isoniazid with HUEXC030 and RZE in?

Isoniazid with HUEXC030 and RZE is in Phase 2.

Related